Are Compounded GLP-1 Medications FDA-Approved?

FDA-approved GLP-1 medications, such as Ozempic, Wegovy, Mounjaro, and Zepbound, have undergone rigorous clinical trials, manufacturing reviews, and regulatory approval processes. Each batch is produced under Current Good Manufacturing Practice (cGMP) regulations and tested for potency, purity, and sterility.

Compounded GLP-1 medications contain the same active pharmaceutical ingredient (semaglutide or tirzepatide) but are prepared by licensed compounding pharmacies rather than the original manufacturer. They are not FDA-approved as finished drug products. This does not mean they are illegal or unsafe. Compounding is a well-established practice regulated at both the federal and state level.

Compounding pharmacies operate under two regulatory frameworks. Section 503A pharmacies are state-licensed and prepare medications based on individual patient prescriptions. They are regulated primarily by state boards of pharmacy and must follow United States Pharmacopeia (USP) standards for sterile and non-sterile compounding.

Section 503B outsourcing facilities are registered with the FDA and can produce compounded medications in larger batches without patient-specific prescriptions. They are subject to FDA inspections, must report adverse events, and follow cGMP-like standards. Medications from 503B facilities generally carry a higher level of quality assurance due to the federal oversight and inspection requirements.

When evaluating a compounded GLP-1 source, 503B outsourcing facilities provide the most robust quality framework outside of FDA-approved manufacturing.

The FDA permits compounding of certain medications when the brand-name versions are listed on the FDA Drug Shortage Database. Both semaglutide and tirzepatide have experienced supply shortages, which has allowed compounding pharmacies to legally produce these medications.

The legal landscape can shift. If the FDA determines that a shortage has been resolved, compounding pharmacies may need to stop producing that specific medication. Patients should stay informed about the current shortage status of their medication and discuss contingency plans with their provider. Your healthcare provider can help you navigate any transitions between compounded and brand-name products.

Reputable compounding pharmacies follow strict quality protocols. These include sterility testing of every batch, potency verification through analytical testing, beyond-use dating based on stability studies, proper storage and shipping conditions (cold chain for injectable medications), and adverse event reporting.

Patients should ask their provider or pharmacy about their quality assurance practices. Key questions include whether the pharmacy is 503A or 503B registered, whether they perform third-party potency and sterility testing, and whether they have had any FDA warning letters or recalls.

Your prescribing provider has a responsibility to source compounded medications from pharmacies with strong quality records. At Weight Method, compounded medications are sourced exclusively from licensed pharmacies that meet rigorous purity and sterility standards.

Choosing a compounded GLP-1 medication is a practical decision that millions of patients make, often driven by cost savings or brand-name supply shortages. The active ingredient in a compounded vial is the same molecule as in the FDA-approved pen.

The trade-off is that compounded products lack the specific FDA approval of the finished product, which means they have not undergone the same clinical trial process as a branded drug. However, the active ingredient itself (semaglutide or tirzepatide) has been thoroughly studied and FDA-approved in its branded forms.

Always discuss the benefits and considerations with your healthcare provider. This content is for educational purposes and should not be taken as medical or legal advice.